Citrine Capital’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.79M Buy
10,523
+55
+0.5% +$14.5K 0.94% 12
2026
Q2
$2.66M Buy
10,468
+15
+0.1% +$3.5K 0.98% 12
2026
Q1
$2.56M Buy
10,453
+553
+6% +$129K 1.11% 12
2025
Q4
$2.05M Buy
9,900
+18
+0.2% +$3.56K 0.95% 12
2025
Q3
$1.83M Hold
9,882
– – 0.85% 12
2025
Q2
$1.51M Hold
9,882
– – 0.8% 14
2025
Q1
$1.64M Hold
9,882
– – 1.03% 12
2024
Q4
$1.43M Buy
+9,882
New +$1.53M 1.05% 14

Other funds holding JNJ

Citrine Capital's JNJ Position: Q3 2026 in Review

Citrine Capital increased its Johnson & Johnson (JNJ) stake by 0.53% in Q3 2026, buying an estimated $14.5K and bringing the position to 10,523 shares worth $2.79M. The position accounts for 0.94% of the portfolio, ranked #12.

Citrine Capital first reported a position in JNJ in Q4 2024 and has held it in 8 quarters since. 4,716 funds tracked by Wall St. Rank hold JNJ as of Q3 2026.

  • Citrine Capital held 10,523 shares of Johnson & Johnson worth $2.79M as of Q3 2026.
  • Citrine Capital bought 55 Johnson & Johnson shares in Q3 2026, an estimated $14.5K.
  • Johnson & Johnson made up 0.94% of Citrine Capital's portfolio in Q3 2026, its #12 holding.
  • Citrine Capital first reported a position in Johnson & Johnson in Q4 2024 and has held it in 8 quarters since.
  • 4,716 funds tracked by Wall St. Rank held Johnson & Johnson as of Q3 2026.

Based on Citrine Capital's 13F filing for Q3 2026, filed 14 Oct 2026.